Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver cancer, colorectal cancer,or con squamous NSCLC. Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred. The study will determine whether MET gene mutation, amplification, as well as MET protein overexpression in tumor tissue correlate with treatment efficacy and clinical outcome. The potential PD biomarker for Metatinib will also be explored.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02650375
Study type Interventional
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact Shuangling Deng, MS
Phone 86-025-85560000
Email dengshuangling@simcere.com
Status Recruiting
Phase Phase 1
Start date October 2015
Completion date February 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05188209 - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. Phase 2
Recruiting NCT04492488 - A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer Phase 1/Phase 2
Completed NCT01512745 - Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Phase 3